### **Company Overview** Cohance Lifesciences Ltd is a global, technology-led **Contract Development and Manufacturing Organization (CRDMO)** formed through the strategic merger of **Suven Pharmaceuticals Ltd** into **Cohance Lifesciences Limited**. Headquartered in Hyderabad, India, with a significant global footprint including a U.S. subsidiary (NJ Bio) in Princeton, New Jersey, Cohance offers integrated end-to-end services from **drug discovery to commercial manufacturing** for pharmaceutical innovators, biotechs, and specialty chemical companies. In FY25, the company generated **INR 26.1 billion (~$313 million)** in revenue with an **industry-leading EBITDA margin of 34%**. It aims to scale to **$1 billion in revenue by 2030** and **$2 billion by 2035**, with over **80% contribution from CDMO services**. --- ### **Strategic Growth Pillars** Cohance’s growth strategy is built on **three core pillars**: 1. **Focus on high-growth, advanced therapeutic modalities** – especially **antibody-drug conjugates (ADCs)** and **oligonucleotide-based therapeutics**. 2. **Targeted M&A** to scale scientific capabilities and enter high-barrier niches. 3. **Operational excellence** through backward integration, advanced chemistry platforms, and scalable, GMP-compliant infrastructure. The company has structured itself into **three focused business units**: - **Pharma CDMO** (37–48% of sales) - **API++** (42–54% of sales) - **Specialty Chemicals CDMO** (7–10% of sales) --- ### **Core Capabilities & Technology Leadership** Cohance has established itself as a **global leader in niche, high-value therapeutic platforms**, supported by proprietary technology and deep scientific expertise. #### **1. Antibody-Drug Conjugates (ADCs) & XDCs** - **End-to-End CRDMO Services**: Covers payload synthesis, linker chemistry, bioconjugation, analytical testing, and fill-finish readiness. - **World-Leading in Camptothecin-Based Payloads**: Supplies intermediates for **two commercially approved ADCs**; holds leadership in the **S-Trione intermediate**. - **Pure-Play Payload Supplier**: Covers **over 75% of the global payload market**, with a proprietary library of **500+ payload-linker combinations**. - **NJ Bio Integration**: Acquisition of **NJ Bio, Inc.** (completed Dec 2024) added **GMP bioconjugation, linker synthesis, and ADC analytics**, enabling **integrated East-West capabilities** (India + U.S.) and positioning Cohance as one of the few **full-spectrum CRDMOs** in the ADC/XDC space. #### **2. Oligonucleotide & Nucleic Acid Therapeutics** - **Tricyclo-DNA (tcDNA) Amidites**: Sole **global commercial supplier** of this proprietary nucleic acid analogue with enhanced stability and binding affinity. - **GalNAc Expertise**: Multi-kilogram-scale synthesis of **high-purity GalNAc compounds** for targeted RNA therapeutics. - **Backward Integration**: Up to **15+ synthesis steps**, ensuring control over critical building blocks. - **Sapala Organics Acquisition**: Strengthened oligonucleotide platform with expertise in **amidites, nucleosides, locked nucleic acids (LNA), and pseudouridine**. #### **3. Advanced Chemistry Platforms** - **High-Potency APIs (HPAPIs)**: Among the top global players in **OEB4–OEB6 containment**, with expanding custom payload capabilities. - **Flow Chemistry & Continuous Manufacturing**: Successfully implemented **CSTR systems** for chiral intermediates, achieving **>99% enantiomeric purity** and improved sustainability. - **Controlled Substances & Narcotics**: Recognized expertise with full backward integration; expanding into **synthetic cannabinoids**. - **Sustainable Catalysis & Complex Small Molecules**: Specialized in **cyanation, heterocyclic, carbohydrate, and chiral chemistry**. --- ### **Strategic Acquisitions (M&A-Driven Growth)** Cohance has built its integrated CDMO platform through a series of high-impact acquisitions, each adding strategic capabilities and geographic reach: | Acquisition | Date | Key Impact | |-----------|------|-----------| | **RA Chem Pharma** | Pre-2023 | Formed the foundation of Cohance’s merchant API and CDMO platform. | | **ZCL Chemicals, Avra Laboratories** | 2023 | Added capabilities in **controlled substances and advanced intermediates**. | | **Sapala Organics** | Jun 2024 (51% stake) | Enhanced **oligonucleotide building block** capabilities; established leadership in **tcDNA and GalNAc**. | | **NJ Bio, Inc.** | Dec 2024 (56% stake) | Acquired **end-to-end ADC CRDMO capabilities** in the U.S., including **bioconjugation, analytical services**, and a strong client base of 150+ innovators. | The combined entity positions Cohance as one of **India’s leading diversified, integrated CDMOs** and among the **top 20 globally**. --- ### **Global Footprint & Infrastructure** - **14 manufacturing plants** and **7 R&D facilities** across India and the U.S. - **Total capacity**: ~3,500 KL (expandable) - **U.S. Presence**: NJ Bio facility in Princeton (80,000 sq ft, GMP and R&D) - **India Sites**: Hyderabad (Nacharam, Genome Valley), Vizag (dedicated to Specialty Chemicals), Suryapet, Jaggaiahpet - **FDA & EU Audited Facilities**: Multiple sites approved by **USFDA, EDQM, PMDA, and EU GMP**, supporting supply into regulated markets. --- ### **Expansion Plans & Capital Expenditure** Cohance is investing heavily to scale capacity and enter commercial-scale manufacturing: - **$10 million expansion** of **cGMP bioconjugation suite** at NJ Bio (Princeton) to support **Phase I–IIb ADC programs**. - **INR 230 million investment** in a **new GMP oligonucleotide building block facility** in **Nacharam, Hyderabad** – expected to be **commercially operational by end-2025**. - Development of **OEB6 containment unit** in India for next-gen payloads. - Ongoing development of **next-generation ADC modalities**: PEGylated antibodies, siRNA conjugates, and **Antibody-Oligonucleotide Conjugates (AOCs)**. --- ### **Customer & Market Positioning** - **Serves 19 of the top 20 global pharmaceutical innovators**, including **14 of the top 20** since the merger. - Over **100 active projects** across **Phase I–III**, with a **Phase III pipeline of 9 molecules** (15 intermediates). - Strong presence in **Japan**, a key innovation hub for nucleic acid therapeutics. - Clients engage under **long-term, patent-aligned supply agreements**, ensuring **annuity-like, defensible revenue streams**. **RFQ/RFP momentum is robust**, especially in **late-phase projects and integrated ADC solutions**, signaling growing market confidence. --- ### **Leadership & Talent** - Led by **Vivek Sharma (Executive Chairman)**, a global pharma CDMO leader with prior experience at **Adare Pharma Solutions**. - Scientific leadership from **Dr. Naresh Jain (NJ Bio)** and **Dr. P. Yella Reddy (Sapala Organics)** strengthens R&D depth. - **Over 510 R&D scientists**, 25% with PhDs, supported by a science-led business development team. - An **External Advisory Board** of five global industry leaders guides strategic direction. --- ### **Key Differentiators** - **Technology-Led CRDMO** with **deep vertical control** across ADC, oligonucleotide, and HPAPI value chains. - **Niche, high-barrier capabilities** (tcDNA, GalNAc, S-Trione, OEB6 containment). - **Dual-geography manufacturing** (India + U.S.). - **Pure-play focus on advanced modalities**, not just capacity. - **Strategic M&A model** to rapidly build domain leadership. ---